- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.11. | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 06.11. | Pharming GAAP EPS of $0.01 beats by $0.01, revenue of $97.3M beats by $4.46M | 4 | Seeking Alpha | ||
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| 06.11. | Pharming Group N.V.: Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow | 343 | GlobeNewswire (Europe) | Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024... ► Artikel lesen | |
| 30.10. | Pharming Group N.V.: Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London | 334 | GlobeNewswire (Europe) | Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare... ► Artikel lesen | |
| 23.10. | Pharming Group N.V.: Pharming Group to report third quarter 2025 financial results and provide business update on November 6 | 307 | GlobeNewswire (Europe) | Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the... ► Artikel lesen | |
| 22.10. | Pharming Group N.V. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 20.10. | Pharming Group N.V.: Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio | 5 | GlobeNewswire (USA) | ||
| 06.10. | Pharming Group N.V.: Pharming Group provides update on previously announced G&A expense reduction plan | 221 | GlobeNewswire (Europe) | Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to... ► Artikel lesen | |
| 03.10. | FDA accepts supplemental New Drug Application for Pharming's paediatric immunodeficiency therapy | 4 | PMLiVE | ||
| 02.10. | Pharming Group-Aktie steigt nach FDA-Zulassung für Leniolisib bei Kindern | 3 | Investing.com Deutsch | ||
| 02.10. | Pharming Group stock rises as FDA approves leniolisib for pediatric APDS | 2 | Investing.com | ||
| 01.10. | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 01.10. | Pharming shares jump 6% as FDA grants priority review for Joenja in children | 4 | Investing.com | ||
| 01.10. | FDA Accepts Pharming's SNDA For Leniolisib In Pediatric APDS; Priority Review Granted | 4 | RTTNews | ||
| 01.10. | Pharming Group N.V.: Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years | 477 | GlobeNewswire (Europe) | If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiencyDecision based... ► Artikel lesen | |
| 10.09. | Pharming Group N.V. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 10.09. | Pharming Group N.V.: Pharming Group promoted to the Euronext AMX index | 282 | GlobeNewswire (Europe) | Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small... ► Artikel lesen | |
| 03.09. | Pharming Group N.V.: Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference | 390 | GlobeNewswire (Europe) | Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27th... ► Artikel lesen | |
| 02.09. | Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus | 25 | Zacks | ||
| 02.09. | Pharming Group N.V. - 6-K, Report of foreign issuer | 3 | SEC Filings |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 7,264 | +0,30 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,208 | +1,96 % | Pacific Biosciences: Mit Long-Read-Sequenzierung zum Angriff auf Illumina | ||
| ATAI BECKLEY | 3,175 | -4,85 % | Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato | ||
| BIOMERIEUX | 108,90 | +0,18 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 1,125 | 0,00 % | Bio Green Med Solution, Inc.: Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update | KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified... ► Artikel lesen | |
| GENUS | 27,600 | -0,72 % | FTSE 250 movers: Genus surges; Workspace slides | ||
| ANAPTYSBIO | 35,600 | -2,20 % | GSK und AnaptysBio verklagen einander wegen angeblicher Lizenzverstöße | DJ GSK und AnaptysBio verklagen einander wegen angeblicher Lizenzverstöße
Von Elena Vardon
DOW JONES--Der Arzneimittelhersteller GSK und das US-Biotechunternehmen AnaptysBio haben einen Rechtsstreit... ► Artikel lesen | |
| ABIONYX PHARMA | 4,160 | +0,24 % | ABIONYX Pharma Reports on Its Business and Cash Position for the Third Quarter of 2025 | Consolidated revenue of €3.06 million at the end of September 2025 Cash position of €2.8 million as of September 30, 2025
Regulatory News:
ABIONYX PharmaFR0012616852 ABNX PEA PME... ► Artikel lesen | |
| AKESO | 12,700 | -0,78 % | Akeso, Inc.: Akeso's Bispecific Antibody Targeting Aß and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China | HONG KONG, Nov. 16, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aß) and... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,745 | -1,32 % | XTL Biopharmaceuticals: CEO Noam Band rückt in den Verwaltungsrat auf | ||
| MEIRAGTX | 6,350 | -3,79 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen | |
| MAAT PHARMA | 3,790 | +0,26 % | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
19.11.2025 / 11:11 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,049 | +1,46 % | Isofol Medical AB: European Patent Office intends to grant a new patent for Isofol's arfolitixorin | GOTHENBURG, Sweden, November 13 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office (EPO) has issued an Intention to Grant notice regarding a... ► Artikel lesen | |
| QIAGEN | 41,790 | +1,79 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,39 | +0,30 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' |
PHARMING GROUP NV ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,70 % bei einem Aktienkurs von 14,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.